Contingent Value Rights (CVRs): Biotech M&A Valuation Bridge

You have seen the letters “CVR” in nearly every biotech M&A headline this year and you have skimmed past them every time. That is the expensive kind of skim. In 2026, the contingent value right became the standard way buyers and sellers bridge the gap between what a seller wants and what a buyer will pay upfront, and the trap is that most of them expire worthless. Here is what a CVR actually is and how to read one.

The one-sentence answer: a CVR is a contingent right to a future cash payment that pays out only if a specific milestone is hit, and the buyer is using it to shift that milestone risk onto the seller while capping its own upfront cash.

Step 1: What a CVR is

A contingent value right (CVR) is a contractual right given to the selling company’s shareholders to receive an additional cash payment if a future milestone is reached. The milestone can be a sales threshold, a regulatory approval, or the monetization of an asset. If the milestone is hit, the holder gets paid. If it is not, the CVR expires worth zero.

A CVR is not the same as an earn-out. An earn-out is usually a private-company mechanism where payment is tied to the acquired business continuing to perform under the buyer. A CVR is a discrete security attached to a public deal, and in biotech it is almost always non-transferable, meaning you cannot sell it. You hold it until it pays out or expires. The Lantheus/Curium acquisition states its CVRs are non-transferable outright.

Step 2: Why biotech uses CVRs specifically

Drug assets have binary, hard-to-price outcomes. Neither side can agree upfront on whether a drug will clear approval or hit a $6 billion sales threshold, so the CVR splits the difference. The buyer pays a base price now, and the seller keeps the upside if the milestone actually lands.

The cleanest example is Gilead’s anito-cel PDUFA analysis. Gilead agreed to pay $115 per share in cash plus one $5 CVR per share for Arcellx, the maker of the CAR-T therapy anito-cel. That extra $5 pays only if cumulative global anito-cel net sales hit $6 billion from launch through year-end 2029. The threshold tells you Gilead’s internal forecast: roughly $1.5 billion a year in anito-cel sales. If your own model is above that, the CVR has value. Below it, the CVR is worth zero. The buyer is literally writing its sales forecast into the deal and making the seller bet on it.

Step 3: Real 2026 deal terms

Three deals with the exact numbers, because the terms are what matter.

Curium / Lantheus: $102.50 per share in cash at closing plus up to $12.00 per share in non-transferable CVRs, tied to specified commercial milestones on Lantheus products through 2030. Full coverage is in the Lantheus/Curium acquisition piece.

Lilly / AtaiBeckley: $2.8 billion upfront, or $6.75 per share in cash, plus up to $2.50 per share in CVRs tied to development and regulatory milestones on the programs BPL-003 and VLS-01, worth up to $1 billion more. Details are in the AtaiBeckley buyout analysis.

Skye / Redx: Skye shareholders received one CVR per share entitling them to 90% of net proceeds from any monetization of the legacy asset nimacimab and its IP within 12 months of closing. This is a monetization CVR, not a sales CVR, and the reverse-merger playbook covers that structure.

Step 4: How to value a CVR

The formula is probability-weighted, then discounted. Value equals the probability the milestone is hit, times the payout, divided by the discount factor for the years you wait.

Two discounts always apply. The first is time: a CVR that pays in 2029 or 2030 is worth less today. The second is illiquidity: a non-transferable CVR cannot be sold, so it carries a steeper discount than a tradeable one.

The market reality is simpler and harsher. Most CVRs trade as a free option priced near zero. Shortly after announcement, Lantheus traded near $100, roughly a 2% discount to the $102.50 cash portion, which meant the up-to-$12 CVR was being priced as essentially worthless. The market’s default assumption is that the milestone will not be hit, and in most cases the market is right.

Step 5: The risks

Most CVRs expire worthless because the milestone is missed and there is no payout.

They are illiquid. Non-transferable means you cannot exit. You hold the risk to the end.

They can be manipulated by the acquirer. The buyer controls the milestone definitions and the post-close product support, and both determine whether the threshold is ever reached. A buyer that wants to avoid paying can redefine “net sales,” slow-walk a launch, or deprioritize the asset after close. Watch the milestone definition, not just the payout number.

Step 6: Where to find the terms

Three places, in order. The deal press release, which gives the headline numbers. The 8-K or merger agreement filed on SEC EDGAR, which has the actual milestone definitions. And the “certain relationships” section of the proxy, which is where the board’s deal rationale and the CVR’s true contingencies live. The CVR terms are the most-skimmed part of any deal filing, and the most likely place the real deal value is hiding. For the pre-deal side, the 8-point M&A screen and the licensing deal economics guide cover how the same logic shows up before a deal is signed.

Common mistakes

Reading the headline deal value as cash. Most of it is contingent, and contingent usually means zero.

Ignoring the milestone definition. “Up to $12” means nothing until you know what has to happen to trigger it, and how the buyer defines the threshold.

Treating a CVR as a tradeable asset. Most are non-transferable, so you cannot sell into a pop.

Modeling the full payout. The base rate is that CVRs expire worthless. Price them near zero and treat any payout as upside, not the thesis.

Final checklist

• What is the guaranteed cash, and what is contingent?
• What milestone triggers the CVR: sales, regulatory, or monetization?
• What is the exact threshold, and who controls the definition after close?
• Is the CVR transferable or locked?
• What probability do you assign the milestone, and at what discount rate?

A CVR is not free money. It is the buyer writing its own forecast into the deal and daring the seller to bet on it. Read the milestone, price it near zero, and let any actual payout be a pleasant surprise.